Chiron Response to ValueAct Letter
16 March 2006 - 8:27AM
Business Wire
Chiron Corporation (NASDAQ:CHIR) today issued the following
statement in response to a letter received today from ValueAct
Capital: We continue to believe that ValueAct should want to meet
with Chiron's independent directors and management team to fully
understand the serious challenges facing the Company and to gain a
realistic perspective on our future prospects. Our independent
directors and management team continue to strongly recommend the
Novartis transaction and believe that it represents a full and fair
price and is a superior alternative for Chiron's public
stockholders to Chiron remaining a standalone company. About Chiron
Chiron delivers innovative and valuable products to protect human
health by advancing pioneering science across the landscape of
biotechnology. The company works to deliver on the limitless
promise of science and make a positive difference in people's
lives. For more information about Chiron, please visit
www.chiron.com.
Chiron (NASDAQ:CHIR)
Historical Stock Chart
From May 2024 to Jun 2024
Chiron (NASDAQ:CHIR)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Chiron (MM) (NASDAQ): 0 recent articles
More Chiron Corporation News Articles